Relmada Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RLMD research report →
Range $12 – $12
Price Chart
About the company
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity.
- CEO
- Sergio Traversa
- IPO
- 2014
- Employees
- 17
- HQ
- Coral Gables, FL, US
Get TickerSpark's AI analysis on RLMD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $279.54M
- P/E
- -3.54
- PEG
- -0.03
- P/S
- 0.00
- P/B
- 1.52
- EV/EBITDA
- -4.17
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -37.25%
- ROIC
- -34.38%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-59,100,200
- Net Income
- $-57,385,163+28.3%
- EPS
- $-1.45+45.3%
- OCF Growth
- +11.5%
- FCF Growth
- +11.5%
- 52W High
- $8.00
- 52W Low
- $2.60
- 50D MA
- $3.64
- 200D MA
- $5.35
- Beta
- 0.45
- RSI (14)
- 34
- Avg Volume
- 1.45M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Relmada said it made meaningful manufacturing progress for NDV-01, reported durable Phase 2 bladder-cancer data, and expects both NDV-01 and sepranolone IND filings by year-end 2026.· November 12, 2026
- NDV-01 remains the lead focus, with management saying IND submission is on track by year-end 2026 and first patient dosing could follow in the first quarter of next year if clearance comes in a reasonable time.
- Phase 2 NDV-01 data continued to look durable: 12 of 14 evaluable patients remained in complete response at 18 months, including 7 of 8 in the BCG-unresponsive subgroup.
- Safety stayed clean in the Phase 2 study, with no Grade 3+ treatment-related adverse events, no treatment-related serious adverse events, and no treatment-related discontinuations.
- Relmada renamed the Phase 3 program SPECTRUM, but said the design is unchanged and includes both a single-arm BCG-unresponsive CIS study and a randomized low-grade intermediate-risk study.
- Cash closed at $202.1 million and management said that should fund operations through 2029, including completion of the Phase 3 SPECTRUM studies.
Relmada closed Q3 2026 with cash, cash equivalents, and short-term investments of $202.1 million, up from $93 million at December 31, 2025. For the quarter, R&D expense was $9.2 million versus $4 million a year ago; G&A expense was $3.9 million versus $6.3 million; net cash used in operating activities was $12.6 million versus $6.7 million; and net loss was $13.9 million, or $0.12 per basic and diluted share, versus a net loss of $10.1 million, or $0.30 per basic and diluted share, in Q3 2025. On the clinical side, 23 high-risk NMIBC patients who were in CR at 12 months entered the long-term extension; 14 were evaluable at 18 months, and 12 remained in CR (86%), including 7 of 8 (88%) in the BCG-unresponsive subgroup. Updated 12-month results in 51 high-risk NMIBC patients showed an anytime CR rate of 94% and a 12-month CR rate of 77%; in the BCG-unresponsive subgroup, anytime CR was 96% and 12-month CR was 73%. No next-quarter financial guidance was provided. Management said it still expects NDV-01 and sepranolone IND submissions by year-end 2026, expects to begin NDV-01 Phase 3 SPECTRUM upon IND clearance, and believes cash can fund operations through 2029.
Sergio Traversa emphasized execution on manufacturing and regulatory readiness, saying the company is making significant progress and remains on track to submit the NDV-01 IND by year-end 2026. He framed NDV-01 as a potentially meaningful bladder-cancer therapy because it combines durability, safety, and convenient in-office use, and he reiterated that sepranolone is also moving toward an IND filing by year-end. His tone was constructive and operationally focused, with repeated emphasis on readiness for the next stage rather than on near-term revenue or commercial metrics.
Maged Shenouda focused on balance sheet strength and expense trends. He said Relmada ended Q3 with $202.1 million in cash, cash equivalents, and short-term investments, up from $93 million at year-end 2025, and said that cash is expected to fund operations through 2029, including the Phase 3 SPECTRUM studies. He also noted R&D rose to $9.2 million from $4 million due mainly to NDV-01 and sepranolone study preparation and manufacturing/storage costs, while G&A fell to $3.9 million from $6.3 million on lower stock-based compensation and stock appreciation rights expense. Net cash used in operations was $12.6 million, and the quarterly net loss was $13.9 million, or $0.12 per share.
Analysts focused on the CIS vs papillary mix, the status of manufacturing/CMC work for the NDV-01 IND, whether the two progressions to muscle-invasive disease had warning signs, and how closely the Phase 2 population maps to the planned second-line SPECTRUM population. Management said the CIS dataset includes pure CIS, CIS Ta, and CIS with T1 patients, but deferred more detail to a future medical meeting; it also said the Phase 2 study was in Israel and they have not yet run the subset analysis for the second-line population. On the MIBC progressions, management said both patients were BCG-naive T1 patients who were responders through 12 months, had no early warning signs, and may have been affected by incomplete maintenance dosing between months 12 and 15. On manufacturing, Sergio said the process was being optimized rather than fixing a single issue, and that stability data look good enough to support the IND.
The bullish case from the call is that NDV-01 is showing unusually durable responses with a clean safety profile, while management is moving the program toward registration with IND filings expected by year-end 2026. The company also has ample cash, which management says should carry it through 2029 and cover the Phase 3 program, reducing financing pressure in the near term.
The main risks are that NDV-01 still has not cleared the IND hurdle, manufacturing remains a work in progress, and management would not provide full detail on the CIS subgroup or the exact second-line population overlap. The two progressions to muscle-invasive disease, plus the need to optimize maintenance/re-induction rules for Phase 3, show that durability and patient selection still need to be proven in later-stage studies.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 83.3%
- Shares Outstanding
- 106.69M
- Float Shares
- 88.89M
of shares held by institutions
131 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for RLMD, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Janus Henderson Group Ltd. | 11.16M | ▲ 11.16M |
| Jupiter Topco LLC | 11.16M | ▲ 11.16M |
| Blackrock, Inc. | 7.58M | ▲ 150.21K |
| Venrock Adviser, LLC | 7.45M | ▲ 600.75K |
| Spruce Street Capital LP | 6.91M | ▲ 520.86K |
| Jones Hill Capital LP | 5.24M | ▲ 1.58M |
| Adage Capital Partners Gp, L.L.C. | 4.76M | 0 |
| Vanguard Capital Management LLC | 4.36M | ▼ 102.24K |
| Ameriprise Financial Inc | 3.72M | ▲ 1.78M |
| Sio Capital Management, LLC | 3.63M | ▲ 2.63M |
| Squadron Capital Management LLC | 3.50M | ▼ 3.85M |
| Millennium Management LLC | 3.35M | ▲ 983.75K |
Held by 125 ETFs
Biggest fund positions in RLMD by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 10, 26 | Shenouda Maged | buy | 79,800 |
| Sep 9, 26 | Shenouda Maged | buy | 120,200 |
| Sep 10, 26 | TRAVERSA SERGIO | buy | 100,000 |
| Sep 9, 26 | TRAVERSA SERGIO | buy | 100,000 |
| Dec 15, 25 | TRAVERSA SERGIO | buy | 27,500 |
| Dec 12, 25 | TRAVERSA SERGIO | other | 1,198,000 |
| Dec 12, 25 | Shenouda Maged | other | 828,000 |
| Dec 15, 25 | Shenouda Maged | buy | 11,665 |
| Dec 12, 25 | Ence Chuck | other | 828,000 |
| Dec 12, 25 | Fedeli Fabiana | other | 164,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RLMD coverage
Recent articles, reports, and earnings notes.
No research on RLMD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RLMD report →Relmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer
globenewswire.com · Nov 16
What Relmada Therapeutics (RLMD) Said on Its Q3 Earnings Call
marketbeat.com · Nov 13
Relmada Therapeutics, Inc. (RLMD) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 12
Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · Nov 12
Relmada Therapeutics to Participate at the Jefferies Global Healthcare Conference in London
globenewswire.com · Nov 4
Relmada Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026
globenewswire.com · Nov 3
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Stock Has Consensus Target Price of $12.00
defenseworld.net · Oct 6
812,059 Shares in Relmada Therapeutics, Inc. $RLMD Purchased by Bank of America Corp DE
defenseworld.net · Sep 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.